Skip to main content
Top
Published in: International Journal of Diabetes in Developing Countries 2/2019

01-04-2019 | Diabetic Nephropathy | Editorial

Normoalbuminuric diabetic kidney disease: a distinct entity?

Author: SV Madhu

Published in: International Journal of Diabetes in Developing Countries | Issue 2/2019

Login to get access

Excerpt

Diabetic kidney disease (DKD) is the major cause of renal disease due to hyperglycemia. Worldwide, approximately 40% of people with diabetes develop DKD. Presence of persistent albuminuria in urine is the initial clinical indication of DKD. Of the major pathways known to be involved in the development and progression of DKD, the renin-angiotensin-aldosterone system (RAAS) has been considered as the most important pathway as it plays a central role in maintaining blood pressure, glomerular pressure, and fluid and electrolyte balance via angiotensin II. During development of diabetic nephropathy (DN), there is increased formation of angiotensin II, by the action of ACE, which further results in renal vascular constriction via activation of its receptor ATR1. However, activation of ATR2 ensues beneficial effects including vasodilation, antiinflammatory, and antiproliferative actions [1]. …
Literature
2.
go back to reference Tsalamandris C, Allen TJ, Gilbert RE, Sinha A, Panagiotopoulos S, Cooper ME, et al. Progressive decline in renal function in diabetic patients with and without albuminuria. Diabetes. 1994;43(5):649–55.CrossRefPubMed Tsalamandris C, Allen TJ, Gilbert RE, Sinha A, Panagiotopoulos S, Cooper ME, et al. Progressive decline in renal function in diabetic patients with and without albuminuria. Diabetes. 1994;43(5):649–55.CrossRefPubMed
3.
go back to reference American Diabetes, A. Standards of medical care in diabetes—2015 abridged for primary care providers. Clin Diabetes : Publ Am Diabetes Assoc. 2015;33(2):97–111.CrossRef American Diabetes, A. Standards of medical care in diabetes—2015 abridged for primary care providers. Clin Diabetes : Publ Am Diabetes Assoc. 2015;33(2):97–111.CrossRef
4.
go back to reference Yokoyama H, Sone H, Oishi M, Kawai K, Fukumoto Y, Kobayashi M, et al. Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management study (JDDM15). Nephrol Dial Transplant. 2008;24(4):1212–9.CrossRefPubMed Yokoyama H, Sone H, Oishi M, Kawai K, Fukumoto Y, Kobayashi M, et al. Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management study (JDDM15). Nephrol Dial Transplant. 2008;24(4):1212–9.CrossRefPubMed
5.
go back to reference Kramer CK, Leitao CB, Pinto LC, Silveiro SP, Gross JL, Canani LH. Clinical and laboratory profile of patients with type 2 diabetes with low glomerular filtration rate and normoalbuminuria. Diabetes Care. 2007;30(8):1998–2000.CrossRefPubMed Kramer CK, Leitao CB, Pinto LC, Silveiro SP, Gross JL, Canani LH. Clinical and laboratory profile of patients with type 2 diabetes with low glomerular filtration rate and normoalbuminuria. Diabetes Care. 2007;30(8):1998–2000.CrossRefPubMed
6.
go back to reference Penno G, et al. Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. J Hypertens. 2011;29(9):1802–9.CrossRefPubMed Penno G, et al. Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. J Hypertens. 2011;29(9):1802–9.CrossRefPubMed
7.
go back to reference Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. Jama. 2003;289(24):3273–7.CrossRefPubMed Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. Jama. 2003;289(24):3273–7.CrossRefPubMed
8.
go back to reference MacIsaac RJ, Panagiotopoulos S, McNeil KJ, Smith TJ, Tsalamandris C, Hao H, et al. Is nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease? Diabetes Care. 2006;29(7):1560–6.CrossRefPubMed MacIsaac RJ, Panagiotopoulos S, McNeil KJ, Smith TJ, Tsalamandris C, Hao H, et al. Is nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease? Diabetes Care. 2006;29(7):1560–6.CrossRefPubMed
9.
go back to reference Boeri D, Derchi LE, Martinoli C, Simoni G, Sampietro L, Storace D, et al. Intrarenal arteriosclerosis and impairment of kidney function in NIDDM subjects. Diabetologia. 1998;41(1):121–4.CrossRefPubMed Boeri D, Derchi LE, Martinoli C, Simoni G, Sampietro L, Storace D, et al. Intrarenal arteriosclerosis and impairment of kidney function in NIDDM subjects. Diabetologia. 1998;41(1):121–4.CrossRefPubMed
10.
go back to reference Lane PH, Steffes MW, Fioretto P, Mauer SM. Renal interstitial expansion in insulin-dependent diabetes mellitus. Kidney Int. 1993;43(3):661–7.CrossRefPubMed Lane PH, Steffes MW, Fioretto P, Mauer SM. Renal interstitial expansion in insulin-dependent diabetes mellitus. Kidney Int. 1993;43(3):661–7.CrossRefPubMed
11.
go back to reference Ekinci EI, Jerums G, Skene A, Crammer P, Power D, Cheong KY, et al. Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal function. Diabetes Care. 2013;36(11):3620–6.CrossRefPubMedPubMedCentral Ekinci EI, Jerums G, Skene A, Crammer P, Power D, Cheong KY, et al. Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal function. Diabetes Care. 2013;36(11):3620–6.CrossRefPubMedPubMedCentral
12.
go back to reference Yagil C, Barak A, Ben-Dor D, Rosenmann E, Bernheim J, Rosner M, et al. Nonproteinuric diabetes-associated nephropathy in the Cohen rat model of type 2 diabetes. Diabetes. 2005;54(5):1487–96.CrossRefPubMed Yagil C, Barak A, Ben-Dor D, Rosenmann E, Bernheim J, Rosner M, et al. Nonproteinuric diabetes-associated nephropathy in the Cohen rat model of type 2 diabetes. Diabetes. 2005;54(5):1487–96.CrossRefPubMed
13.
go back to reference Boronat M, García-Cantón C, Quevedo V, Lorenzo DL, López-Ríos L, Batista F, et al. Non-albuminuric renal disease among subjects with advanced stages of chronic kidney failure related to type 2 diabetes mellitus. Ren Fail. 2014;36(2):166–70.CrossRefPubMed Boronat M, García-Cantón C, Quevedo V, Lorenzo DL, López-Ríos L, Batista F, et al. Non-albuminuric renal disease among subjects with advanced stages of chronic kidney failure related to type 2 diabetes mellitus. Ren Fail. 2014;36(2):166–70.CrossRefPubMed
14.
go back to reference Alter ML, Kretschmer A, von Websky K, Tsuprykov O, Reichetzeder C, Simon A, et al. Early urinary and plasma biomarkers for experimental diabetic nephropathy. Clin Lab. 2012;58(7–8):659–71.PubMed Alter ML, Kretschmer A, von Websky K, Tsuprykov O, Reichetzeder C, Simon A, et al. Early urinary and plasma biomarkers for experimental diabetic nephropathy. Clin Lab. 2012;58(7–8):659–71.PubMed
15.
go back to reference Chen, C.-M., S.-H. Juan, and H.-C. Chou, Hyperglycemia activates the renin-angiotensin system and induces epithelial-mesenchymal transition in streptozotocin-induced diabetic kidneys. J Renin-Angiotensin-Aldosterone Syst, 2018. 19(3): p. 1470320318803009, 147032031880300. Chen, C.-M., S.-H. Juan, and H.-C. Chou, Hyperglycemia activates the renin-angiotensin system and induces epithelial-mesenchymal transition in streptozotocin-induced diabetic kidneys. J Renin-Angiotensin-Aldosterone Syst, 2018. 19(3): p. 1470320318803009, 147032031880300.
16.
go back to reference Noronha IL, Fujihara CK, Zatz R. The inflammatory component in progressive renal disease—are interventions possible? Nephrol Dial Transplant. 2002;17(3):363–8.CrossRefPubMed Noronha IL, Fujihara CK, Zatz R. The inflammatory component in progressive renal disease—are interventions possible? Nephrol Dial Transplant. 2002;17(3):363–8.CrossRefPubMed
17.
go back to reference Durvasula RV, Petermann AT, Hiromura K, Blonski M, Pippin J, Mundel P, et al. Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int. 2004;65(1):30–9.CrossRefPubMed Durvasula RV, Petermann AT, Hiromura K, Blonski M, Pippin J, Mundel P, et al. Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int. 2004;65(1):30–9.CrossRefPubMed
18.
go back to reference Ruiz-Ortega M, Lorenzo Ó, Rupérez M, Blanco J, Egido J. Systemic infusion of angiotensin II into normal rats activates nuclear factor-κB and AP-1 in the kidney: role of AT1 and AT2 receptors. Am J Pathol. 2001;158(5):1743–56.CrossRefPubMedPubMedCentral Ruiz-Ortega M, Lorenzo Ó, Rupérez M, Blanco J, Egido J. Systemic infusion of angiotensin II into normal rats activates nuclear factor-κB and AP-1 in the kidney: role of AT1 and AT2 receptors. Am J Pathol. 2001;158(5):1743–56.CrossRefPubMedPubMedCentral
19.
go back to reference Lee FT, Cao Z, Long DM, Panagiotopoulos S, Jerums G, Cooper ME, et al. Interactions between angiotensin II and NF-κB–dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. J Am Soc Nephrol. 2004;15(8):2139–51.CrossRefPubMed Lee FT, Cao Z, Long DM, Panagiotopoulos S, Jerums G, Cooper ME, et al. Interactions between angiotensin II and NF-κB–dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. J Am Soc Nephrol. 2004;15(8):2139–51.CrossRefPubMed
20.
go back to reference Esteban V, Lorenzo O, Rupérez M, Suzuki Y, Mezzano S, Blanco J, et al. Angiotensin II, via AT1 and AT2 receptors and NF-κB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J Am Soc Nephrol. 2004;15(6):1514–29.CrossRefPubMed Esteban V, Lorenzo O, Rupérez M, Suzuki Y, Mezzano S, Blanco J, et al. Angiotensin II, via AT1 and AT2 receptors and NF-κB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J Am Soc Nephrol. 2004;15(6):1514–29.CrossRefPubMed
21.
go back to reference Soler MJ, Ye M, Wysocki J, William J, Lloveras J, Batlle D. Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. Am J Physiol-Renal Physiol. 2009;296(2):F398–405.CrossRefPubMed Soler MJ, Ye M, Wysocki J, William J, Lloveras J, Batlle D. Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. Am J Physiol-Renal Physiol. 2009;296(2):F398–405.CrossRefPubMed
22.
go back to reference Nikzamir A, Nakhjavani M, Esteghamati A, Rashidi A. Correlates of ACE activity in macroalbuminuric type 2 diabetic patients treated with chronic ACE inhibition. Nephrol Dial Transplant. 2007;23(4):1274–7.CrossRefPubMed Nikzamir A, Nakhjavani M, Esteghamati A, Rashidi A. Correlates of ACE activity in macroalbuminuric type 2 diabetic patients treated with chronic ACE inhibition. Nephrol Dial Transplant. 2007;23(4):1274–7.CrossRefPubMed
23.
24.
go back to reference Chandra S, et al. Association of angiotensin II type 1 receptor (A1166C) gene polymorphism and its increased expression in essential hypertension: a case-control study. PLoS One. 2014;9(7):e101502-e101502.CrossRef Chandra S, et al. Association of angiotensin II type 1 receptor (A1166C) gene polymorphism and its increased expression in essential hypertension: a case-control study. PLoS One. 2014;9(7):e101502-e101502.CrossRef
25.
go back to reference Shah VN, Cheema BS, Sharma R, Khullar M, Kohli HS, Ahluwalia TS, et al. ACACβ gene (rs2268388) and AGTR1 gene (rs5186) polymorphism and the risk of nephropathy in Asian Indian patients with type 2 diabetes. Mol Cell Biochem. 2013;372(1):191–8.CrossRefPubMed Shah VN, Cheema BS, Sharma R, Khullar M, Kohli HS, Ahluwalia TS, et al. ACACβ gene (rs2268388) and AGTR1 gene (rs5186) polymorphism and the risk of nephropathy in Asian Indian patients with type 2 diabetes. Mol Cell Biochem. 2013;372(1):191–8.CrossRefPubMed
26.
go back to reference Moradi M, et al. AT1R A1166C variants in patients with type 2 diabetes mellitus and diabetic nephropathy. J Nephropathol. 2015;4(3):69–76.PubMedPubMedCentral Moradi M, et al. AT1R A1166C variants in patients with type 2 diabetes mellitus and diabetic nephropathy. J Nephropathol. 2015;4(3):69–76.PubMedPubMedCentral
27.
go back to reference Viswanathan V, Krishnamoorthy E, Kumpatla S, et al. Clinical and biochemical characteristics and the association of angiotensin type 1 receptor with normoalbuminuric chronic kidney disease among South Indian type 2 diabetes population. Int J Diabetes Dev Ctries. 2019. https://doi.org/10.1007/s13410-019-00719-0. Viswanathan V, Krishnamoorthy E, Kumpatla S, et al. Clinical and biochemical characteristics and the association of angiotensin type 1 receptor with normoalbuminuric chronic kidney disease among South Indian type 2 diabetes population. Int J Diabetes Dev Ctries. 2019. https://​doi.​org/​10.​1007/​s13410-019-00719-0.
Metadata
Title
Normoalbuminuric diabetic kidney disease: a distinct entity?
Author
SV Madhu
Publication date
01-04-2019
Publisher
Springer India
Published in
International Journal of Diabetes in Developing Countries / Issue 2/2019
Print ISSN: 0973-3930
Electronic ISSN: 1998-3832
DOI
https://doi.org/10.1007/s13410-019-00751-0

Other articles of this Issue 2/2019

International Journal of Diabetes in Developing Countries 2/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.